BRPI0914943A2 - anticorpos de il-6 e sua utilizaÇço - Google Patents

anticorpos de il-6 e sua utilizaÇço

Info

Publication number
BRPI0914943A2
BRPI0914943A2 BRPI0914943-0A2A BRPI0914943A BRPI0914943A2 BR PI0914943 A2 BRPI0914943 A2 BR PI0914943A2 BR PI0914943 A BRPI0914943 A BR PI0914943A BR PI0914943 A2 BRPI0914943 A2 BR PI0914943A2
Authority
BR
Brazil
Prior art keywords
antibodies
Prior art date
Application number
BRPI0914943-0A2A
Other languages
English (en)
Inventor
Arvind Rajpal
Madhav Devalaraja
Kristopher Toy
Lan Yang
Halichun Huang
Jun Z Zhang
Peter Brams
Brigitte Devaux
David B Passmore
Original Assignee
Bristol Myers Squibb Co
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41431517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914943(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Pfizer filed Critical Bristol Myers Squibb Co
Publication of BRPI0914943A2 publication Critical patent/BRPI0914943A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
BRPI0914943-0A2A 2008-06-18 2009-06-10 anticorpos de il-6 e sua utilizaÇço BRPI0914943A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7343008P 2008-06-18 2008-06-18
US12/480,991 US8188235B2 (en) 2008-06-18 2009-06-09 Antibodies to IL-6 and their uses
PCT/US2009/046837 WO2009155180A1 (en) 2008-06-18 2009-06-10 Antibodies to il-6 and their uses

Publications (1)

Publication Number Publication Date
BRPI0914943A2 true BRPI0914943A2 (pt) 2013-09-17

Family

ID=41431517

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914943-0A2A BRPI0914943A2 (pt) 2008-06-18 2009-06-10 anticorpos de il-6 e sua utilizaÇço

Country Status (22)

Country Link
US (4) US8188235B2 (pt)
EP (1) EP2291404A1 (pt)
JP (2) JP2011524750A (pt)
KR (1) KR20110031152A (pt)
CN (2) CN102083860B (pt)
AR (1) AR072167A1 (pt)
AU (1) AU2009260320B2 (pt)
BR (1) BRPI0914943A2 (pt)
CA (1) CA2724257A1 (pt)
CO (1) CO6351748A2 (pt)
IL (2) IL208532A0 (pt)
MX (1) MX2010012272A (pt)
NZ (1) NZ588469A (pt)
PA (1) PA8830701A1 (pt)
PE (2) PE20140825A1 (pt)
PH (1) PH12013502205A1 (pt)
RU (1) RU2011101589A (pt)
SG (1) SG194358A1 (pt)
TW (1) TW201002348A (pt)
UY (1) UY31904A (pt)
WO (1) WO2009155180A1 (pt)
ZA (1) ZA201006979B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
KR20110094307A (ko) * 2008-11-13 2011-08-23 펨타 파마슈티컬스, 인크. 인간화된 항-ｉｌ-6 항체
JP5933264B2 (ja) 2009-07-16 2016-06-08 サンスター株式会社 プロテオグリカン含有物
EP2547352A4 (en) * 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
WO2011133748A1 (en) * 2010-04-21 2011-10-27 University Of Medicine And Dentistry Of New Jersey Treatments for cellular proliferative disorders and identification thereof
WO2012032181A2 (en) * 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
US9284359B2 (en) 2011-01-19 2016-03-15 Hirosaki University Method for mass preparation of proteoglycan
TWI452688B (zh) 2011-12-27 2014-09-11 Ind Tech Res Inst 可撓式輻射感測器
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
SG11201500211PA (en) * 2012-07-25 2015-03-30 Univ Hirosaki Composition for preventing or treating osteoarthritis
TWI500629B (zh) * 2012-10-22 2015-09-21 Fountain Biopharma Inc 介白素－６抗體及其用途
JP2016519145A (ja) * 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
US9268032B2 (en) 2014-05-12 2016-02-23 Industrial Technology Research Institute Electrical radiography imaging system and method thereof
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
CA2916283C (en) 2015-01-09 2024-07-02 Pfizer Inc. MADCAM ANTAGONIST DOSING REGIMEN
CA3119498A1 (en) 2015-07-31 2017-02-09 Medimmune Limited Methods for treating hepcidin-mediated disorders
RU2021129189A (ru) * 2016-01-22 2021-11-15 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
MY201852A (en) 2016-06-14 2024-03-20 Merck Sharp & Dohme Llc Anti-coagulation factor xi antibodies
TWI716668B (zh) 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
CN110655576A (zh) * 2019-11-13 2020-01-07 武汉华美生物工程有限公司 Il-6重组单克隆抗体及其制备方法和应用
KR20250107839A (ko) * 2022-11-11 2025-07-14 투르말린 바이오, 인코퍼레이티드 심혈관계 질환의 치료 방법
EP4623002A2 (en) * 2022-11-23 2025-10-01 Tourmaline Bio, Inc. Methods for the treatment of thyroid eye disease
US20250066467A1 (en) * 2022-11-23 2025-02-27 Tourmaline Bio, Inc. Methods for the treatment of myasthenia gravis
WO2024129468A1 (en) * 2022-12-16 2024-06-20 Tourmaline Bio, Inc. Methods for the treatment of noninfectious uveitis
IL327070A (en) * 2023-09-28 2026-05-01 Tourmaline Bio Inc Methods for treating cardiovascular diseases
WO2025106642A1 (en) * 2023-11-14 2025-05-22 Tourmaline Bio, Inc. Methods for the treatment of thyroid eye disease
WO2025122924A1 (en) * 2023-12-07 2025-06-12 Tourmaline Bio, Inc. Methods for the prevention and treatment of long covid and related symptoms

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326859A (en) * 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US5554513A (en) * 1979-11-21 1996-09-10 Yeda Research & Development Co. Ltd. Production of recombinant human interferon-beta2
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JP2598666B2 (ja) 1987-10-19 1997-04-09 忠三 岸本 抗ヒトｂｃｄｆモノクローナル抗体
US5210116A (en) * 1988-01-19 1993-05-11 Yazaki Corporation Resin composite material containing graphite fiber
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
US6682896B1 (en) * 1988-10-14 2004-01-27 Schering Aktiengesellschaft Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0399429A1 (en) 1989-05-22 1990-11-28 Toray Industries, Inc. Anti-human interleukin-6 monoclonal antibody
JP2881311B2 (ja) 1989-07-28 1999-04-12 味の素株式会社 抗ヒトｂｃｄｆモノクローナル抗体及びそれを用いたヒトｂｃｄｆの定量法
DE3939706C1 (pt) 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
AU648777B2 (en) 1989-12-04 1994-05-05 Schering Corporation Method of treating septic shock
JPH05503098A (ja) 1989-12-15 1993-05-27 カイロン　コーポレイション セプシスの処理のためのサイトカイン抗体
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
JP3525221B2 (ja) 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
US5891998A (en) * 1993-06-23 1999-04-06 Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. Interleukin-6 receptor agonists
CN1502331A (zh) 1993-07-19 2004-06-09 Ѫ�ܼ���ҩ�﹫˾ 抗血管生长组合物及使用方法
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
FR2707882B1 (fr) * 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
US5641657A (en) * 1994-05-19 1997-06-24 Human Genome Sciences, Inc. DNA encoding an interleukin-6 splice variant
JPH10503179A (ja) * 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5738931A (en) * 1994-09-16 1998-04-14 Kabushiki Kaisha Toshiba Electronic device and magnetic device
ATE552012T1 (de) 1994-10-07 2012-04-15 Chugai Pharmaceutical Co Ltd Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
IT1274782B (it) * 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
AU704723B2 (en) * 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
DK0811384T3 (da) * 1995-02-13 2006-10-09 Chugai Pharmaceutical Co Ltd Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
IT1276555B1 (it) * 1995-04-28 1997-11-03 Angeletti P Ist Richerche Bio Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5854398A (en) * 1996-07-25 1998-12-29 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof
US6461604B1 (en) * 1996-08-16 2002-10-08 Genetics Institute, Llc Crystalline IL-6 and models of the molecular structure of IL-6
WO1999013092A1 (en) 1997-09-11 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. Enhancement of mucosal antibody responses by interleukin-6
PT1074268E (pt) 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
ES2276525T3 (es) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
PL356836A1 (en) 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
WO2002034292A1 (fr) * 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
WO2002072788A2 (en) 2001-03-14 2002-09-19 Centocor, Inc. Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
WO2003083061A2 (en) 2002-03-26 2003-10-09 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003261787B2 (en) * 2002-08-30 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
WO2004045507A2 (en) 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004071404A2 (en) 2003-02-04 2004-08-26 Centocor Inc. Use of il-6 antagonists in combination with steroids to enhance apoptosis
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005028514A1 (en) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Use of a compound for reducing the biological effectiveness of il-6
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
FI20050753A7 (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP1960434B1 (en) 2005-12-08 2012-07-11 Medarex, Inc. Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
EA200870130A1 (ru) * 2005-12-30 2009-02-27 Мерк Патент Гмбх Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
AU2007282023B2 (en) 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
TW201531484A (zh) * 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses

Also Published As

Publication number Publication date
CA2724257A1 (en) 2009-12-23
US8436158B2 (en) 2013-05-07
CN104387471A (zh) 2015-03-04
IL208532A0 (en) 2010-12-30
AU2009260320B2 (en) 2014-10-30
MX2010012272A (es) 2010-12-02
PE20110561A1 (es) 2011-08-11
CN102083860B (zh) 2014-12-03
CO6351748A2 (es) 2011-12-20
PH12013502205A1 (en) 2015-10-12
CN102083860A (zh) 2011-06-01
PA8830701A1 (es) 2010-04-21
AU2009260320A8 (en) 2011-11-10
NZ588469A (en) 2012-09-28
UY31904A (es) 2009-12-14
PE20140825A1 (es) 2014-07-18
EP2291404A1 (en) 2011-03-09
RU2011101589A (ru) 2012-07-27
US20090317402A1 (en) 2009-12-24
AU2009260320A1 (en) 2009-12-23
US20120202285A1 (en) 2012-08-09
US20150203574A1 (en) 2015-07-23
AR072167A1 (es) 2010-08-11
US8846037B2 (en) 2014-09-30
TW201002348A (en) 2010-01-16
JP2015166366A (ja) 2015-09-24
SG194358A1 (en) 2013-11-29
JP2011524750A (ja) 2011-09-08
IL232276A0 (en) 2014-06-30
WO2009155180A8 (en) 2011-01-20
HK1155184A1 (en) 2012-05-11
WO2009155180A1 (en) 2009-12-23
US8188235B2 (en) 2012-05-29
US20130280266A1 (en) 2013-10-24
ZA201006979B (en) 2012-06-27
KR20110031152A (ko) 2011-03-24

Similar Documents

Publication Publication Date Title
IL271270A (en) Antibodies to 6-il and their use
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
IL287311A (en) Antibodies and processes for preparing the same
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK3338799T3 (da) Antistoffer til il-6 og anvendelse deraf
CY2016029I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
HUE038501T2 (hu) Antitest készítmények
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
EP2207803A4 (en) Cd9-specific human antibodies
HUE056626T2 (hu) Antitestkészítmény
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0809677A2 (pt) Anticorpos anti-ige
DK2131860T3 (da) Anti-sclerostin-antistoffer
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0820819A2 (pt) Formulação de anticorpos
PT2195026E (pt) Anticorpos anti-esclerostina
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0920850A2 (pt) novos compostos e sua utilização
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0909633A2 (pt) anticorpos anti-tyrp1
BRPI0912769A2 (pt) anticorpos anti-pirb
TH0901005240A (th) แอนติ-เฟอร์โรพอร์ติน 1 โมโนโคลนอลแอนติบอดี และการใช้ของมัน

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]